DNLI · Insider Trading
Denali Therapeutics Inc. Common Stock
Every open-market purchase and sale reported by DNLI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | Peter Scott Chin | Chief Medical Officer | Sell | −1,654 | −$36.87K |
| 2026-09-04 | Nancy Thornberry | Director | Sell | −11,439 | −$261.93K |
| 2026-09-03 | Alexander O. Schuth | COFO and Secretary | Sell | −2,768 | −$64.88K |
| 2026-08-14 | Ryan J. Watts | President and CEO | G | −32,220 | — |
| 2026-08-13 | Alexander O. Schuth | COFO and Secretary | Sell | −2,857 | −$71.62K |
| 2026-06-05 | Jennifer E. Cook | Director | A | +6,408 | — |
| 2026-06-05 | David P Schenkein | Director | A | +6,408 | — |
| 2026-06-05 | Peter S Klein | Director | A | +6,408 | — |
| 2026-06-05 | Nancy Thornberry | Director | A | +6,408 | — |
| 2026-06-05 | Timothy Van Hauwermeiren | Director | A | +6,408 | — |
| 2026-06-05 | Steve E. Krognes | Director | A | +6,408 | — |
| 2026-06-05 | Jay T Flatley | Director | A | +6,408 | — |
| 2026-06-05 | Baker Bros. Advisors (GP) LLC | Director | A | +76,896 | — |
| 2026-01-08 | Alexander O. Schuth | COFO and Secretary | Sell | −17,218 | −$284.10K |
| 2026-01-08 | Ryan J. Watts | President and CEO | Sell | −35,198 | −$580.77K |
| 2026-01-05 | Ryan J. Watts | President and CEO | A | +78,960 | — |
| 2026-01-05 | Alexander O. Schuth | COFO and Secretary | A | +57,700 | — |
| 2025-12-15 | 667, L.P. | Director | Buy | +13,714,284 deriv. | — |
| 2025-11-06 | Timothy Van Hauwermeiren | Director | A | +10,632 | — |
| 2025-09-05 | Ryan J. Watts | President and CEO | G | −50,000 | — |
| 2025-08-14 | Carole Ho | Chief Medical Officer | Sell | −3,743 | −$51.68K |
| 2025-08-14 | Alexander O. Schuth | COFO and Secretary | Sell | −2,937 | −$39.88K |
| 2025-08-07 | Carole Ho | Chief Medical Officer | M | +44,655 | +$30.37K |
| 2025-07-11 | Ryan J. Watts | President and CEO | MIXED | — | −$6.91M |
| 2025-06-05 | Jennifer E. Cook | Director | A | +6,037 | — |
| 2025-06-05 | Peter S Klein | Director | A | +6,037 | — |
| 2025-06-05 | Steve E. Krognes | Director | A | +6,037 | — |
| 2025-06-05 | Jay T Flatley | Director | A | +6,037 | — |
| 2025-06-05 | David P Schenkein | Director | A | +6,037 | — |
| 2025-06-05 | Nancy Thornberry | Director | A | +6,037 | — |
| 2025-06-05 | Julian Baker | Director | A | +126,780 | — |
| 2025-06-05 | Marc Tessier-Lavigne | Director | A | +6,037 | — |
| 2025-01-08 | Steve E. Krognes | Director | Sell | −3,339 | −$69.48K |
| 2025-01-08 | Carole Ho | Chief Medical Officer | Sell | −15,162 | −$308.29K |
| 2025-01-08 | Alexander O. Schuth | COFO and Secretary | Sell | −15,162 | −$308.29K |
| 2025-01-08 | Ryan J. Watts | President and CEO | Sell | −36,916 | −$750.96K |
| 2025-01-07 | Ryan J. Watts | President and CEO | A | +54,180 | — |
| 2025-01-07 | Carole Ho | Chief Medical Officer | A | +54,180 | — |
| 2025-01-07 | Alexander O. Schuth | COFO and Secretary | A | +54,180 | — |
| 2025-01-03 | Vicki L Sato | Director | Sell | −3,080 | −$64.40K |
| 2025-01-03 | Steve E. Krognes | Director | Sell | −30,000 | −$607.50K |
| 2024-12-31 | Alexander O. Schuth | COFO and Secretary | M | +6,708 | +$35.42K |
| 2024-11-27 | Carole Ho | Chief Medical Officer | M | +17,845 | +$12.13K |
| 2024-11-26 | Alexander O. Schuth | COFO and Secretary | M | +20,516 | +$13.95K |
| 2024-11-13 | David P Schenkein | Director | MIXED | −12,276 | −$1.08M |
| 2024-11-12 | Vicki L Sato | Director | Sell | −1,020 | −$30.60K |
| 2024-11-12 | Alexander O. Schuth | COFO and Secretary | MIXED | — | −$383.14K |
| 2024-11-05 | Vicki L Sato | Director | Sell | −3,080 | −$83.38K |
| 2024-10-22 | Ryan J. Watts | President and CEO | MIXED | — | −$1.08M |
| 2024-10-02 | Steve E. Krognes | Director | Sell | −30,000 | −$870.90K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Baker Bros. Advisors (GP) LLC | Director | 3,422,366 | $66.02M |
| Julian Baker | Director | 3,415,958 | $65.89M |
| Ryan J. Watts | President and CEO | 2,417,217 | $46.63M |
| Marc Tessier-Lavigne | Director | 1,965,424 | $37.91M |
| Steve E. Krognes | Director | 819,999 | $15.82M |
| Alexander O. Schuth | COFO and Secretary | 802,744 | $15.48M |
| Jay T Flatley | Director | 358,941 | $6.92M |
| Carole Ho | Chief Medical Officer | 242,391 | $4.68M |
| Peter Scott Chin | Chief Medical Officer | 204,538 | $3.95M |
| Vicki L Sato | Director | 107,976 | $2.08M |
| David P Schenkein | Director | 52,897 | $1.02M |
| Peter S Klein | Director | 33,941 | $654.72K |
| Jennifer E. Cook | Director | 32,483 | $626.60K |
| Nancy Thornberry | Director | 19,686 | $379.74K |
| Timothy Van Hauwermeiren | Director | 17,040 | $328.70K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DNLI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.